Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System

This article was originally published in PharmAsia News

Executive Summary

Novartis is concerned that the changing intricacies of the Indian legal system will indefinitely delay its court case challenging the Indian Patent Office's denial of the Gleevec (imatinib) patent in the developing country

Related Content

Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)
Intellectual Property In India: Novartis Gleevec Patent Battle Will Go On Without Government Document Supporting “Evergreening” (Part 1 of 3)



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts